3-hydroxyquinazoline derivatives, analogues of erastin, induce ferroptosis in colorectal cancer cells

Мұқаба

Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Тек жазылушылар үшін

Аннотация

In recent years, significant progress has been achieved in the treatment of patients with colon cancer, but in most cases treatment is accompanied by the development of drug resistance. Recently discovered iron-dependent cell death, ferroptosis, makes it a promissing therapeutic target to reduce the recurrence rates. In this study we have examined the effect of 3-hydoxyquinazoline derivatives on ferroptosis induction in two colon cancer cells HCT-116 and DLD-1. The ferroptotic cell death was identified by the level of lipid peroxidation. The level of lipid peroxidation in HCT-116 cells induced by some compounds approached the activity of the reference drug erastin. This scenario changed significantly when the ferroptosis induction was studied in DLD-1 cells. Two 3-hydroxyquinazoline derivatives induced levels of lipid peroxidation in DLD-1 cells that exceeded those of erastin. The preliminary results obtained suggest that three new compounds can be considered as an antitumor agent for the treatment of colon cancer, and also indicate the prospects of further searching for ferroptosis inducers among 3-hydroxyquinazoline derivatives.

Толық мәтін

Рұқсат жабық

Авторлар туралы

V. Osipov

N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia

Хат алмасуға жауапты Автор.
Email: ovn65@yandex.ru
Ресей, Kashirskoe shosse 24, Moscow, 115478

A. Vartanyan

N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia

Email: ovn65@yandex.ru
Ресей, Kashirskoe shosse 24, Moscow, 115478

D. Khochenkov

N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia

Email: ovn65@yandex.ru
Ресей, Kashirskoe shosse 24, Moscow, 115478

D. Gusev

N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia

Email: ovn65@yandex.ru
Ресей, Kashirskoe shosse 24, Moscow, 115478

O. Fateenkova

I.M. Sechenov First Moscow State Medical University of the Ministry of Health of Russia (Sechenov University)

Email: ovn65@yandex.ru
Ресей, ul. Trubetskaya 8/2, Moscow, 119991

D. Khachatryan

National Research Center “Kurchatov Institute”

Email: ovn65@yandex.ru
Ресей, pl. Akad. Kurchatova 1, Moscow, 123182

L. Borisova

N.N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia

Email: ovn65@yandex.ru
Ресей, Kashirskoe shosse 24, Moscow, 115478

Әдебиет тізімі

  1. Fabregas J.C., Ramnaraign B., George T.J. // Clin. Colorectal Cancer. 2022. V. 21. P. 198–203. https://doi.org/10.1016/j.clcc.2022.05.006
  2. Grazzini G., Danti G., Chiti G., Giannessi C., Pradella S., Miele V. // Diagnostics (Basel). 2023. V. 13. P. 2104–2115. https://doi.org/10.3390/diagnostics13122104
  3. Afrăsânie V.A., Marinca M.V., Alexa-Stratulat T., Gafton B., Păduraru M., Adavidoaiei A.M., Miron L., Rusu C. // Radiol. Oncol. 2019. V. 53. P. 265–274. https://doi.org/10.2478/raon-2019-0033
  4. Kozovska Z., Gabrisova V., Kucerova L. // Biomed. Pharmacother. 2014. V. 68. P. 911–916. https://doi.org/10.1016/j.biopha.2014.10.019
  5. Van der Jeught K., Xu H.C., Li Y.J., Lu X.B., Ji G. // World J. Gastroenterol. 2018. V. 24. P. 3834–3848. https://doi.org/10.3748/wjg.v24.i34.3834
  6. Dixon S.J., Lemberg K.M., Lamprecht M.R., Skouta R., Zaitsev E.M., Gleason C.E., Patel D.N., Bauer A.J., Cantley A.M., Yang W.S., Morrison B., 3rd, Stockwell B.R. // Cell. 2012. V. 149. P. 1060–1072. https://doi.org/10.1016/j.cell.2012.03.042
  7. Negri F., Bottarelli L., de’Angelis G.L., Gnetti L. // Int. J Mol. Sci. 2022. V. 23. P. 4120–4128. https://doi.org/10.3390/ijms23084120
  8. Zhang C., Liu X., Jin S., Chen Y., Guo R. // Mol. Cancer. 2022. V. 21. P. 47–59. https://doi.org/10.1186/s12943-022-01530-y
  9. Prutki M., Poljak-Blazi M., Jakopovic M., Tomas D., Stipancic I., Zarkovic N. // Cancer Lett. 2006. V. 238. P. 188–96. https://doi.org/10.1016/j.canlet.2005.07.001
  10. Demir H., Beypinar I., Urvay S., Davarci S.E., Baykara M. // Eur. Rev. Med. Pharmacol. Sci. 2021. V. 25. P. 6473–6479. https://doi.org/10.26355/eurrev_202111_27091
  11. Xu T., Ding W., Ji X., Ao X., Liu Y., Yu W., Wang J. // J. Cell Mol Med. 2019. V. 23. P. 4900–4912. https://doi.org/10.1111/jcmm.14511
  12. Galluzzi L., Vitale I., Warren S., Adjemian S., Agostinis P., Martinez A.B., Chan T.A., Coukos G., Demaria S., Deutsch E., Draganov D., Edelson R.L., Formenti S.C., Fucikova J., Gabriele L., Gaipl U.S., Gameiro S.R., Garg A.D., Golden E., Han J., Harrington K.J., Hemminki A., Hodge J.W., Hossain D.M.S., Illidge T., Karin M., Kaufman H.L., Kepp O., Kroemer G., Lasarte J.J., Loi S., Lotze M.T., Manic G., Merghoub T., Melcher A.A., Mossman K.L., Prosper F., Rekdal Ø., Rescigno M., Riganti C., Sistigu A., Smyth M.J., Spisek R., Stagg J., Strauss B.E., Tang D., Tatsuno K., van Gool S.W., Vandenabeele P., Yamazaki T., Zamarin D., Zitvogel L., Cesano A., Marincola F.M. // J. Immunother. Cancer. 2020. V. 8. P. e000337. https://doi.org/10.1136/jitc-2019-000337
  13. Sprooten J., De Wijngaert P., Vanmeerbeerk I., Martin S., Vangheluwe P., Schlenner S., Krysko D.V., Parys J.B., Bultynck G., Vandenabeele P., Garg A.D. // Cells. 2020. V. 9. P. 1823. https://doi.org/10.3390/cells9081823
  14. Wiernicki B., Maschalidi S., Pinney J., Adjemian S., Vanden Berghe T., Ravichandran K.S., Vandenabeele P. // Nat. Commun. 2022. V. 13. P. 3676. https://doi.org/10.1038/s41467-022-31218-2
  15. Борисова Л.М., Осипов В.Н., Гусев Д.В. Голубева И.С., Киселева М.П., Вартанян А.А. // Рос. биотерапевтич. журнал. 2021. Т. 20. С. 67–73. https://doi.org/10.17650/1726-9784-2021-20-1-67-73
  16. Борисова Л.М., Осипов В.Н., Голубева И.С., Киселева М.П., Хоченков Д.А., Вартанян А.А. // Усп. мол. онкологии. 2022. Т. 9. С. 48–56. https://doi.org/10.17650/2313-805X-2022-9-1-48-56
  17. Wang Y., Wu X., Ren Z., Li Y., Zou W., Chen J., Wang H. // Drug Resist. Updat. 2023. V. 66. P. 100916. https://doi.org/10.1016/j.drup.2022.100916
  18. Вартанян А.А., Осипов В.Н., Хоченков Д.А., Гусев Д.В., Борисова Л.М. // Патент RU 2722308 С1, опубл. 28.05.2020.
  19. Trainer D.L., Kline T., McCabe F.L., Faucette L.F., Feild J., Chaikin M., Anzano M., Rieman D., Hoffstein S., Li D.J., Gennaro D., Buscarino C., Lynch M., Poste G., Greig R. // Int. J. Cancer. 1988. V. 41. P. 287–296. https://doi.org/10.1002/ijc.2910410221
  20. Chen S.K., Ma W.Q., Yan Z.B., Zhang F.M., Wang S.H., Nu Y.Q., Zhang X.M., Tian J.M. // J. Am. Chem. Soc. 2018. V. 140. P. 10099–10103. https://doi.org/10.3389/fphar.2017.00992
  21. Martinez A.M., Kim A., Yang W.S. // Methods Mol. Biol. 2020. V. 2108. P. 125–130. https://doi.org/10.1007/978-1-0716-0247-8_11
  22. Sakata S., Larson D.W. // Surg. Oncol. Clin. N. Am. 2022. V. 31. P. 255–264. https://doi.org/10.1016/j.soc.2021.11.006
  23. Zhang C., Liu X., Jin S., Chen Y., Guo R. // Mol. Cancer. 2022. V. 21. P. 47–58. https://doi.org/10.1186/s12943-022-01530-y

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу
2. Fig. 1. Effect of compound (VIIa) on the induction of ferroptosis in HCT-116 cells: (a) – control – cell growth with 5% DMSO; (b) – cell growth with 1/3 IC50 erastin; (c) – cell growth with 1/3 IC50 of compound (VIIa). Scale bar – 100 µm.

Жүктеу (151KB)
Метадеректер
3. Fig. 2. Quantitative characteristics of the intensity of lipid peroxidation in HCT-116 and DLD-1 cells. K – fluorescence intensity induced by erastin, 1–7 – compounds (VIIa–g), respectively. Data are presented as mean ± standard deviation, p < 0.05.

Жүктеу (69KB)
Метадеректер
4. Scheme 1. Synthesis of 3-hydroxyquinozaline derivatives. Reagents and conditions: i – CH2Cl2/H2O, thiophosgene; ii – AcONa, H2O; iii – NaOH, NH2OH . HCl, H2O; iv – NH2NH2 . H2O, ethanol; v – acetylacetone, ethanol; vi – benzyl chloroacetate, K2CO3, DMF.

Жүктеу (94KB)
Метадеректер
5. Tab. 1, fig. 1

Жүктеу (23KB)
Метадеректер
6. Tab. 1, fig. 2

Жүктеу (23KB)
Метадеректер
7. Tab. 1, fig. 3

Жүктеу (23KB)
Метадеректер
8. Tab. 1, fig. 4

Жүктеу (23KB)
Метадеректер
9. Tab. 1, fig. 5

Жүктеу (22KB)
Метадеректер
10. Tab. 1, fig. 6

Жүктеу (22KB)
Метадеректер
11. Tab. 1, fig. 7

Жүктеу (23KB)
Метадеректер
12. Tab. 1, fig. 8

Жүктеу (27KB)
Метадеректер

© Russian Academy of Sciences, 2024